<DOC>
	<DOC>NCT01681953</DOC>
	<brief_summary>The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis</brief_summary>
	<brief_title>A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis</brief_title>
	<detailed_description />
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<criteria>Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trialrelated activities The subject and his/her guardian(s) must have the ability to comply with the protocol The subject must have a confirmed diagnosis of alphaMannosidosis as defined by alphaMannosidase activity &lt; 10% of normal activity (historical data) The subject must have an age at the time of screening ≥ 5 years and ≤ 35 years The subject must have the ability to physically and mentally cooperate in the tests The subject must have an ECHO without abnormalities that, in the opinion of the Investigator, would preclude participation in the trial The subjects diagnosis cannot be confirmed by alphaMannosidase activity &lt; 10% of normal activity The subject cannot walk without support Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alphaMannosidosis History of BMT Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial Pregnancy: Pregnant woman is excluded. Before start of the treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception Psychosis; any psychotic disease, also in remission, is an exclusion criteria Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial Participation in other interventional trials testing IMP (including Lamazym) within the last 3 months Adult patients who, in the opinion of the Investigator, would be unable to give consent, and who does not have any legal protection or guardianship Total IgE &gt;800 IU/ml Known allergy to the IMP or any excipients (SodiumPhosphate, Glycine, Mannitol)</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>